The MagnetisMM studies are committed to finding potential treatment options
We know it takes a full support system to take on multiple myeloma. And we’re here to explore a potential way to fight it with you.
The MagnetisMM clinical research studies will evaluate the safety and effectiveness of a study medicine, elranatamab, in people with multiple myeloma. Participating in a study is an important and personal decision. We want you to know that we will be with you every step of the way.
Each MagnetisMM study will have its own unique requirements for who may participate called eligibility criteria.
The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received.
You can talk with the study doctor to find out which study may be right for you.
Condition
Multiple myeloma
Age
18+ years
Sex
Male or Female
This information is a summary of the eligibility criteria across the studies in this program. Each study will have its own unique requirements for who may participate called eligibility criteria. To learn more about the requirements for a study that is actively recruiting, visit the study’s webpage below. Only the research study staff can determine if you qualify to enroll in the study.
Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumors and leaving a person vulnerable to infection.
The study medicine, elranatamab, is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells (cancer cells). Connecting these cells activates the immune cells, potentially killing the myeloma cells.
Immunomodulatory drugs (IMiDs) help adjust the immune response to kill cancer cells or make it difficult for them to grow. Anti-CD38 antibodies such as daratumumab kill cancer cells and may alter the immune response. Proteasome inhibitors (PIs) kill cancer cells by causing excess protein to build up inside of them. B-cell maturation antigen (BCMA) antibodies target a protein found on the surface of myeloma cells.
Relapse is when a treatment works for a while and then stops. Refractory is when a disease doesn’t respond to treatment. Relapsed/refractory multiple myeloma refers to multiple myeloma that either comes back after responding to treatment or doesn’t respond to treatment at all.
The study medicine and all study-related care and procedures are provided at no cost. You don’t need health insurance to join a clinical study. However, you (or your health insurance provider) may be responsible for medical expenses that are part of your usual healthcare. Talk with your study team or review the informed consent document to find out exactly what is covered.
Travel to the study center and other expenses (such as meals) may be covered. Please discuss the details with your study team.
Your health information and any data that could be used to identify you (such as immigration status) will be kept private and safe. Only information that relates to the study will be collected, and only your study team, study doctor, and organizations that oversee the study will be able to access it. Your personal information won’t be shared with third parties such as the government or advertisers.
Multiple myeloma is a type of blood cancer that forms in your bone marrow. Multiple myeloma starts when healthy plasma cells change and grow at a rapid pace.
Abnormal plasma cells also build up in your bones and organs, making it difficult for them to work properly.
The MagnetisMM studies will evaluate the safety and effectiveness of the study medicine, elranatamab, which will be given as a subcutaneous (SC) injection. An SC injection is a needle inserted under the skin in order to deliver the study medicine.
Elranatamab is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.
Diversity among study participants is important in order to understand whether potential treatments work in different people. Race, ethnicity, age, and sex can all impact how different people respond to the same treatment.
When groups of people aren’t well represented in research, we cannot know if the study medicine may work properly for all the people it is trying to help.
When you take part in a study, you’re helping to represent both your community and all people who are affected by multiple myeloma.
